By Elric Langton | 29 March 2022
SkinBioTherapeutics plc (AIM: SBTX), a life sciences company focused on skin health, announces its unaudited half-year consolidated results for the six months to 31 December 2021. It seems crass to say the market did not like what it saw or read coming from the Company. So when investors read a line saying revenues will be “materially below market expectations,” it came as no surprise the market makers were eager to drop the share price to 29p to sell before the bell.
